Form 4 for TRDA Entrada Therapeutics, Inc.
Accepted 2022-08-18 00:00:00 ET · period of report 2022-08-16 · accession 0001104659-22-092658 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-08-18 | 2022-08-16+ | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +300 | 20.6K | +1% | +$630 |
| DM | 2022-08-18 | 2022-08-16+ | TRDA | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $13.02 | -600 | 20.2K | -3% | -$7,814 |
| DM | 2022-08-18 | 2022-08-16+ | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $0.00 | -300 | 115.9K | -0.3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-18 | M | A | 100 | $2.10 | 20,441 | D | — | — | |
| 2 | Common | Common Stock | 2022-08-17 | S | D | 200 | $13.07 | 20,341 | D | — | — | |
| 3 | Common | Common Stock | 2022-08-17 | M | A | 100 | $2.10 | 20,541 | D | — | — | |
| 4 | Common | Common Stock | 2022-08-16 | S | D | 200 | $13.00 | 20,441 | D | — | — | |
| 5 | Common | Common Stock | 2022-08-16 | M | A | 100 | $2.10 | 20,641 | D | — | — | |
| 6 | Common | Common Stock | 2022-08-18 | S | D | 200 | $13.00 | 20,221 | D | — | — | |
| 7 | Derivative | Stock Option (Right to Buy) | 2022-08-16 | M | D | 100 | $0.00 | 116,096 | D | $2.10 · — to 2030-11-10 | 100 Common Stock | (F2) 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
| 8 | Derivative | Stock Option (Right to Buy) | 2022-08-17 | M | D | 100 | $0.00 | 115,996 | D | $2.10 · — to 2030-11-10 | 100 Common Stock | (F2) 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
| 9 | Derivative | Stock Option (Right to Buy) | 2022-08-18 | M | D | 100 | $0.00 | 115,896 | D | $2.10 · — to 2030-11-10 | 100 Common Stock | (F2) 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. |